In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom

References

• Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. Nat Rev Dis Primer. 2017;3:1–11.
   Web of Science ®Google Scholar
• Viravan C, Veeravat U, Warrell MJ, Theakston RDG, Warrell DA. ELISA confirmation of acute and past envenoming by the monocellate Thai Cobra (Naja kaouthia). Am J Trop Med Hyg. 1986;35:173–81. doi:10.4269/ajtmh.1986.35.173
   PubMed Web of Science ®Google Scholar
• Warrell D. 1995. Clinical Toxicology of Snakebite in Asia. In: Meier J, White J, editors. . Handbook of clinical toxicology of animal venoms and poisons. Boca Raton, FL, USA: CRC Press. pp. 493–594.
   Google Scholar
• Asia RO for S-E ARO, Organization WH. 2016. Guidelines for the management of snakebites [Internet]. WHO Regional Office for South-East Asia; [accessed 2022 June 8]. https://apps.who.int/iris/handle/10665/249547
   Google Scholar
• Warrell D. 1995. Handbook of clinical toxicology of animal venoms and poisons. In: Meier J, White J, editors. Toxicon. Vol. 35. Boca Raton (FL): CRC Press; p. 752.
   Google Scholar
• Alkondon M, Albuquerque EX. alpha-Cobratoxin blocks the nicotinic acetylcholine receptor in rat hippocampal neurons. Eur J Pharmacol. 1990;191:505–06. doi:10.1016/0014-2999(90)94190-9
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Gutiérrez JM, Lohse B, Rasmussen AR, Fernández J, Milbo C, Lomonte B. Snake venomics of monocled cobra (Naja kaouthia) and investigation of human IgG response against venom toxins. Toxicon Off J Int Soc Toxinology. 2015a;99:23–35. doi:10.1016/j.toxicon.2015.03.001
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Lohse B, Lomonte B, Engmark M, Gutiérrez JM. Selecting key toxins for focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score. Toxicon Off J Int Soc Toxinology. 2015b;104:43–45. doi:10.1016/j.toxicon.2015.07.334
   PubMed Web of Science ®Google Scholar
• León G, Vargas M, Segura Á, Herrera M, Villalta M, Sánchez A, Solano G, Gómez A, Sánchez M, Estrada R, et al. Current technology for the industrial manufacture of snake antivenoms. Toxicon Off J Int Soc Toxinology. 2018;151:63–73. doi:10.1016/j.toxicon.2018.06.084
   PubMedGoogle Scholar
• León G, Herrera M, Segura Á, Villalta M, Vargas M, Gutiérrez JM. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon Off J Int Soc Toxinology. 2013;76:63–76. doi:10.1016/j.toxicon.2013.09.010
   PubMed Web of Science ®Google Scholar
• Laustsen AH. How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases? Expert Opin Drug Discov. 2019;14:1103–12. doi:10.1080/17460441.2019.1646723
   PubMed Web of Science ®Google Scholar
• Harrison RA, Gutiérrez JM. Priority actions and progress to substantially and sustainably reduce the mortality, morbidity and socioeconomic burden of tropical snakebite. Toxins. 2016;8:351.
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Engmark M, Clouser C, Timberlake S, Vigneault F, Gutiérrez JM, Lomonte B. Exploration of immunoglobulin transcriptomes from mice immunized with three-finger toxins and phospholipases A2 from the Central American coral snake, Micrurus nigrocinctus. PeerJ. 2017;5:e2924. doi:10.7717/peerj.2924
   PubMed Web of Science ®Google Scholar
• Tan NH, Wong KY, Tan CH. Venomics of Naja sputatrix, the Javan spitting cobra: a short neurotoxin-driven venom needing improved antivenom neutralization. J Proteomics. 2017;157:18–32. doi:10.1016/j.jprot.2017.01.018
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Gutiérrez JM, Rasmussen AR, Engmark M, Gravlund P, Sanders KL, Lohse B, Lomonte B. Danger in the reef: proteome, toxicity, and neutralization of the venom of the olive sea snake, Aipysurus laevis. Toxicon. 2015;107:187–96. doi:10.1016/j.toxicon.2015.07.008
   PubMed Web of Science ®Google Scholar
• Tan CH, Tan KY, Lim SE, Tan NH. Venomics of the beaked sea snake, Hydrophis schistosus: a minimalist toxin arsenal and its cross-neutralization by heterologous antivenoms. J Proteomics. 2015;126:121–30. doi:10.1016/j.jprot.2015.05.035
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, Lohse B. From fangs to pharmacology: the future of snakebite envenoming therapy. Curr Pharm Des. 2016;22:5270–93. doi:10.2174/1381612822666160623073438
   PubMed Web of Science ®Google Scholar
• Kini RM, Sidhu SS, Laustsen AH. Biosynthetic Oligoclonal Antivenom (BOA) for snakebite and next-generation treatments for snakebite victims. Toxins. 2018;10:534. doi:10.3390/toxins10120534
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Karatt-Vellatt A, Masters EW, Arias AS, Pus U, Knudsen C, Oscoz S, Slavny P, Griffiths DT, Luther AM, et al. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nat Commun. 2018;9:3928. doi:10.1038/s41467-018-06086-4
   PubMed Web of Science ®Google Scholar
• Laustsen AH. Snakebites: costing recombinant antivenoms. Nature. 2016;538:41–41. doi:10.1038/538041e
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: a cost-competitive solution to a neglected tropical disease? PLoS Negl Trop Dis. 2017;11:e0005361. doi:10.1371/journal.pntd.0005361
   PubMed Web of Science ®Google Scholar
• Jenkins TP, Laustsen AH. 2020. Cost of manufacturing for recombinant snakebite antivenoms. Front Bioeng Biotechnol. 8: 703. https://www.frontiersin.org/articles/10.3389/fbioe.2020.00703/full doi:10.3389/fbioe.2020.00703. 32766215.
   PubMed Web of Science ®Google Scholar
• Richard G, Meyers AJ, McLean MD, Arbabi-Ghahroudi M, MacKenzie R, Hall JC. In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc Antibody. PLOS ONE. 2013;8:e69495. doi:10.1371/journal.pone.0069495
   PubMed Web of Science ®Google Scholar
• Kulkeaw K, Sakolvaree Y, Srimanote P, Tongtawe P, Maneewatch S, Sookrung N, Tungtrongchitr A, Tapchaisri P, Kurazono H, Chaicumpa W. Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J Proteomics. 2009;72:270–82. doi:10.1016/j.jprot.2008.12.007
   PubMed Web of Science ®Google Scholar
• Schofield DJ, Pope AR, Clementel V, Buckell J, Chapple SD, Clarke KF, Conquer JS, Crofts AM, Crowther SR, Dyson MR, et al. Application of phage display to high throughput antibody generation and characterization. Genome Biol. 2007;8:R254. doi:10.1186/gb-2007-8-11-r254
   PubMed Web of Science ®Google Scholar
• Martin CD, Rojas G, Mitchell JN, Vincent KJ, Wu J, McCafferty J, Schofield DJ. A simple vector system to improve performance and utilisation of recombinant antibodies. BMC Biotechnol. 2006;6:46. doi:10.1186/1472-6750-6-46
   PubMed Web of Science ®Google Scholar
• Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By–passing immunization: building high affinity human antibodies by Chain shuffling. Bio/Technology. 1992;10:779–83.
   PubMed Web of Science ®Google Scholar
• Casewell NR, Jackson TNW, Laustsen AH, Sunagar K. Causes and consequences of snake venom variation. Trends Pharmacol Sci. 2020;41:570–81. doi:10.1016/j.tips.2020.05.006
   PubMed Web of Science ®Google Scholar
• Lewin M, Samuel S, Merkel J, Bickler P. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins. 2016;8:248. doi:10.3390/toxins8090248
   PubMed Web of Science ®Google Scholar
• Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75:69–75. doi:10.1016/S0163-7258(97)00023-5
   PubMed Web of Science ®Google Scholar
• Laustsen AH, Gutiérrez JM, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, Jürgensen JA, Ledsgaard L, Martos-Esteban A, Øhlenschlæger M, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 2018;146:151–75. doi:10.1016/j.toxicon.2018.03.004
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PWA, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6:38644. doi:10.1038/srep38644
   PubMed Web of Science ®Google Scholar
• Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M, et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. mAbs. 2020;12:1829335. doi:10.1080/19420862.2020.1829335
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci. 2017;114:944–49. doi:10.1073/pnas.1616408114
   PubMed Web of Science ®Google Scholar
• Bailly M, Mieczkowski C, Juan V, Metwally E, Tomazela D, Baker J, Uchida M, Kofman E, Raoufi F, Motlagh S, et al. Predicting antibody developability profiles through early stage discovery screening. mAbs. 2020;12:1743053. doi:10.1080/19420862.2020.1743053
   PubMed Web of Science ®Google Scholar
• Ratanabanangkoon K, Simsiriwong P, Pruksaphon K, Tan KY, Chantrathonkul B, Eursakun S, Tan CH. An in vitro potency assay using nicotinic acetylcholine receptor binding works well with antivenoms against Bungarus candidus and Naja naja. Sci Rep. 2018;8:9716. doi:10.1038/s41598-018-27794-3
   PubMed Web of Science ®Google Scholar
• S-X L, Huang S, Bren N, Noridomi K, Dellisanti CD, Sine SM, Chen L. Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist. Nat Neurosci. 2011;14:1253–59. doi:10.1038/nn.2908
   PubMed Web of Science ®Google Scholar